Presently, Christopher H. Cabell is Chief Medical Officer & Head-Clinical Development at Emergent BioSolutions, Inc. Dr. Cabell is also on the board of ScienceMedia, Inc. and Pulmatrix, Inc. and Member of American College of Cardiology Foundation.

Dr. Cabell previously held the position of Co-Chairman at Cardiac Safety Research Consortium, Senior VP & Head-Therapeutic Delivery Unit at Quintiles Transnational Corp. and Chief Medical & Scientific Officer at IQVIA RDS, Inc. (North Carolina) (a subsidiary of Quintiles Transnational Corp.), Co-Chairman of US Food & Drug Administration, Chief Medical & Scientific Officer at IQVIA, Inc., Chief Medical Officer, Head-Research & Development at Arena Pharmaceuticals, Inc. and Director-Echocardiography Core Lab at Duke Clinical Research Institute.

Dr. Cabell received a graduate degree from Duke University, an undergraduate degree from The Pennsylvania State University and a doctorate from Duke University School of Medicine.